What are CCR5 antagonist drugs?

CCR5 antagonist drugs are pharmacologic agents that share a common mechanism (typically targeting CCR5 (C-C chemokine receptor type 5)). 1 are currently marketed, with 3 more in clinical development.

What are the marketed CCR5 antagonist drugs?

Marketed CCR5 antagonist drugs include Maraviroc (MVC).

CCR5 antagonist

1 marketed 2 in Phase 3 1 in Phase 2

This page covers all CCR5 antagonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CCR5 (C-C chemokine receptor type 5), CCR5.

Targets

CCR5 (C-C chemokine receptor type 5) · CCR5

Marketed (1)

Maraviroc (MVC) · National Institute of Allergy and Infectious Diseases (NIAID) · Infectious Disease / Virology
Maraviroc blocks the CCR5 chemokine receptor on the surface of CD4+ T cells, preventing HIV from entering and infecting these immune cells.

Phase 3 pipeline (2)

Celsentri® · Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer · Infectious Disease
Celsentri is a CCR5 antagonist that blocks the CCR5 co-receptor on CD4+ T cells, preventing HIV entry and infection.
Maraviroc (Celsentri) · ANRS, Emerging Infectious Diseases · Infectious Disease
Maraviroc blocks the CCR5 chemokine receptor on the surface of CD4+ T cells, preventing HIV from entering and infecting these immune cells.

Phase 2 pipeline (1)

HIV Anti-retroviral Background Therapy · Theratechnologies · Infectious Disease
Inhibits HIV replication by targeting the CCR5 receptor